The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Treatment of Acquired Hypothalamic Obesity: Now and the Future
Abstract
The hypothalamus is the centre of neuroendocrine regulation of energy homeostasis and appetite. Maldevelopment of, or damage to, the key hypothalamic nuclei disrupts the coordinated balance between energy intake and expenditure leading, to rapid and excessive weight gain. Hypothalamic obesity is compounded by a disruption of the hypothalamic-pituitary axis, sleep disruption, visual compromise, and neurological and vascular sequalae. Amongst suprasellar tumors, craniopharyngioma is the most common cause of acquired hypothalamic obesity, either directly or following surgical or radiotherapeutic intervention. At present, therapy is limited to strategies to manage obesity but with a modest and variable impact. Current approaches include optimizing pituitary hormone replacement, calorie restriction, increased energy expenditure through physical activity, behavioral interventions, pharmacotherapy and bariatric surgery. Current pharmacotherapeutic approaches include stimulants that increase energy consumption, anti-diabetic agents, hypothalamic–pituitary substitution therapy, octreotide, and methionine aminopeptidase 2 (MetAP2) inhibitors. Some pharmacological studies of hypothalamic obesity report weight loss or stabilization but reported intervention periods are short, and others report no effect. The impact of bariatric surgery on weight loss in hypothalamic obesity again is variable. Novel or combined approaches to manage hypothalamic obesity are thus required to achieve credible and sustained weight loss. Identifying etiological factors contributing hypothalamic obesity may lead to multi-faceted interventions targeting hyperphagia, insulin resistance, decreased energy expenditure, sleep disturbance, hypopituitarism and psychosocial morbidity. Placebo-controlled trials using current single, or combination therapies are required to determine the impact of therapeutic agents. A well-defined approach to defining the location of hypothalamic damage may support the use of future targeted therapies. Intranasal oxytocin is currently being investigated as an anorexogenic agent. Novel agents including those targeting pro-opimelanocortin-C and AgRP/NPY expressing neurons and the MC4 receptor may result in better outcomes. This article discusses the current challenges in the management of hypothalamic obesity in children and young people and future therapeutic approaches to increasing weight loss and quality of life in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Several pharmaceutical interventions have been reported to be effective for hypothalamic hyperphagia, although this is also not one size fits all with, in each study, responders and nonresponders (3, 19, 118).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503
Taheri, S., Lin, L., Austin, D., Young, T., & Mignot, E. (2004) · PLoS Medicine · doi:10.1371/journal.pmed.0010062 · Cited by 2,477
Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356
Role of Brain Insulin Receptor in Control of Body Weight and Reproduction
Brüning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Müller-Wieland, D., & Kahn, C. R. (2000) · Science · doi:10.1126/science.289.5487.2122 · Cited by 2,235
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998
Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons
Woods, S. C., Lotter, E. C., McKay, L. D., & Porte, D. (1979) · Nature · doi:10.1038/282503a0 · Cited by 1,114
Impact of insufficient sleep on total daily energy expenditure, food intake, and weight gain
Markwald, R. R., Melanson, E. L., Smith, M. R., Higgins, J., Perreault, L., Eckel, R. H., & Wright, K. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216951110 · Cited by 810
Neurobiology of food intake in health and disease
Morton, G. J., Meek, T. H., & Schwartz, M. W. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3745 · Cited by 748 · cited 2×
“Leptin appears to potentiate this effect by directly and indirectly enhancing the response of the NTS to gut peptides and leptin is increased in patients with hypothalamic obesity (6, 27, 104, 105).”
BackgroundDecreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats
Obici, S., Feng, Z., Karkanias, G., Baskin, D. G., & Rossetti, L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-861 · Cited by 719
Shekelle, P. G., Hardy, M. L., Morton, S. C., Maglione, M., Mojica, W. A., Suttorp, M. J., Rhodes, S. L., Jungvig, L., & Gagné, J. (2003) · JAMA · doi:10.1001/jama.289.12.1537 · Cited by 511
Research works printed but not linked: 122
- von Mohr, 1840, Hypertrophie Der Hypophysis Cerebri Und Dadurch Bedingter Druck Auf Die Hirngrundfläche, Insbesondere Auf Die Sehnerven, Das Chiasma Desselben Und Den Linksseitigen Hirnschenkel, Wochenschr Ges Heilkd, 6
- Nevin, 1939, Hypothalamic and Pituitary Tumours, Postgrad Med J, 15, 10.1136/pgmj.15.163.210 · doi:10.1136/pgmj.15.163.210
- 1936, A Report of the Henderson Trust Lectures, Edinb Med J, 43
- Brobeck, 1943, Experimental Hypothalamic Hyperphagia in the Albino Rat, Yale J Biol Med, 15
- Kennedy, 1953, The Role of Depot Fat in the Hypothalamic Control of Food Intake in the Rat, Proc R Soc Lond B, 140, 10.1098/rspb.1953.0009 · DOI · Paper page
- Timper, 2017, Hypothalamic Circuits Regulating Appetite and Energy Homeostasis: Pathways to Obesity, Dis Models Mech, 10, 10.1242/dmm.026609 · DOI · Paper page
- Roh, 2016, Emerging Role of the Brain in the Homeostatic Regulation of Energy and Glucose Metabolism, Exp Mol Med, 48, e216, 10.1038/emm.2016.4 · DOI · Paper page
- Miura, 1996, Muscarinic Stimulation Increases Na+ Entry in Pancreatic B-Cells by a Mechanism Other Than the Emptying of Intracellular Ca2+ Pools, Biochem Biophys Res Commun, 224, 67, 10.1006/bbrc.1996.0985 · DOI
- Arbuzova, 1998, MARCKS, Membranes, and Calmodulin: Kinetics of Their Interaction, Biochim Biophys Acta, 1376, 10.1016/S0304-4157(98)00011-2 · DOI
- Blondel, 1994, Creation of an Inositol 1,4,5-Trisphosphate-Sensitive Ca2+ Store in Secretory Granules of Insulin-Producing Cells, J Biol Chem, 269, 10.1016/S0021-9258(18)46962-1 · doi:10.1016/s0021-9258(18)46962-1
- Lausier, 2010, Vagal Control of Pancreatic ß-Cell Proliferation, Am J Physiol Endocrinol Metab, 299, 10.1152/ajpendo.00202.2010 · DOI
- Inoue, 1977, The Effects of Subdiaphragmatic Vagotomy in Rats With Ventromedial Hypothalamic Obesity, Endocrinology, 100, 10.1210/endo-100-1-108 · DOI · Paper page
- Pandit, 2017, Role of Leptin in Energy Expenditure: The Hypothalamic Perspective, Am J Physiol Regul Integr Comp Physiol, 312, 10.1152/ajpregu.00045.2016 · DOI · Paper page
- Collins, 2012, β-Adrenoceptor Signaling Networks in Adipocytes for Recruiting Stored Fat and Energy Expenditure, Front Endocrinol (Lausanne), 2, 10.3389/fendo.2011.00102 · DOI · Paper page
- Ollmann, 1997, Antagonism of Central Melanocortin Receptors In Vitro and In Vivo by Agouti-Related Protein, Science, 278, 10.1126/science.278.5335.135 · DOI · Paper page
- Considine, 1996, Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans, N Engl J Med, 334, 10.1056/NEJM199602013340503 · DOI · Paper page
- Cohen, 2001, Selective Deletion of Leptin Receptor in Neurons Leads to Obesity, J Clin Invest, 108, 10.1172/JCI200113914 · DOI
- Sohn, 2013, Melanocortin 4 Receptors Reciprocally Regulate Sympathetic and Parasympathetic Preganglionic Neurons, Cell, 152, 10.1016/j.cell.2012.12.022 · DOI · Paper page
- Rezai-Zadeh, 2014, Leptin Receptor Neurons in the Dorsomedial Hypothalamus are Key Regulators of Energy Expenditure and Body Weight, But Not Food Intake, Mol Metab, 3, 10.1016/j.molmet.2014.07.008 · DOI · Paper page
- Ono, 2019, Molecular Mechanisms of Hypothalamic Insulin Resistance, Int J Mol Sci, 20, 1317, 10.3390/ijms20061317 · DOI
- Dodd, 2017, Insulin Action in the Brain: Roles in Energy and Glucose Homeostasis, J Neuroendocrinol, 29, (10), 10.1111/jne.12513 · DOI
- De Vile, 1996, Obesity in Childhood Craniopharyngioma: Relation to Post-Operative Hypothalamic Damage Shown by Magnetic Resonance Imaging, J Clin Endocrinol Metab, 81, 10.1210/jcem.81.7.8675604 · doi:10.1210/jcem.81.7.8675604 · Paper page
- Müller, 2011, Study Committee of KRANIOPHARYNGEOM 2000. Post-Operative Hypothalamic Lesions and Obesity in Childhood Craniopharyngioma: Results of the Multinational Prospective Trial KRANIOPHARYNGEOM 2000 After 3-Year Follow-Up, Eur J Endocrinol, 165, 17, 10.1530/EJE-11-0158 · DOI · Paper page
- Müller, 2001, Obesity After Childhood Craniopharyngioma–German Multicenter Study on Pre-Operative Risk Factors and Quality of Life, Klin Padiatr, 213, 10.1055/s-2001-16855 · DOI · Paper page
- Muller, 2008, Childhood Craniopharyngioma. Recent Advances in Diagnosis, Treatment and Follow-Up, Horm Res, 69, 193, 10.1159/000113019 · DOI · Paper page
- Hoffman, 1992, Aggressive Surgical Management of Craniopharyngiomas in Children (1992), J Neurosurg, 76, 47, 10.3171/jns.1992.76.1.0047 · DOI · Paper page
- Ahmet, 2006, Weight Gain in Craniopharyngioma–A Model for Hypothalamic Obesity, J Pediatr Endocrinol Metab, 19, 10.1515/JPEM.2006.19.2.121 · DOI
- Wu, 2021, Risk Factors for Hypothalamic Obesity in Patients With Adult-Onset Craniopharyngioma: A Consecutive Series of 120 Cases, Front Endocrinol (Lausanne), 12, 10.3389/fendo.2021.694213 · DOI
- Van Iersel, 2018, The Development of Hypothalamic Obesity in Craniopharyngioma Patients: A Risk Factor Analysis in a Well-Defined Cohort, Pediatr Blood Cancer, 65, e26911, 10.1002/pbc.26911 · DOI
- Roth, 1998, Hyperphagia in Children With Craniopharyngioma Is Associated With Hyperleptinemia and a Failure in the Down Regulation of Appetite, Eur J Endocrinol, 138, 89, 10.1530/eje.0.1380089 · DOI · Paper page
- Holmer, 2010, Reduced Energy Expenditure and Impaired Feeding-Related Signals But Not High Energy Intake Reinforces Hypothalamic Obesity in Adults With Childhood Onset Craniopharyngioma, J Clin Endocrinol Metab, 95, 10.1210/jc.2010-0993 · DOI
- Shaikh, 2008, Reductions in Basal Metabolic Rate and Physical Activity Contribute to Hypothalamic Obesity, J Clin Endocrinol Metab, 93, 10.1210/jc.2007-2672 · DOI
- Roth, 2007, Reduced Sympathetic Metabolites in Urine of Obese Patients With Craniopharyngioma, Pediatr Res, 61, 496, 10.1203/pdr.0b013e3180332cd6 · DOI · Paper page
- Coutant, 2003, Defect in Epinephrine Production in Children With Craniopharyngioma: Functional or Organic Origin, J Clin Endocrinol Metab, 88, 10.1210/jc.2003-030552 · DOI
- Caldarelli, 2005, Long-Term Results of the Surgical Treatment of Craniopharyngioma: The Experience at the Policlinico Gemelli, Catholic University, Rome, Child’s Nervous System, 21, 10.1007/s00381-005-1186-5 · DOI · Paper page
- Hoffman, 2004, Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial, J Clin Endocrinol Metab, 89, 10.1210/jc.2003-030346 · DOI · Paper page
- Fulton, 1929, Tumors in the Region of the Third Ventricle: Their Diagnosis and Relation to Pathological Sleep, J Nervous Ment Dis, 69, 10.1097/00005053-192902000-00003 · DOI
- Cordani, 2021, Sleep Disturbances in Craniopharyngioma: A Challenging Diagnosis, J Neurol, 268, 10.1007/s00415-021-10794-1 · DOI
- Müller, 2002, Melatonin Secretion and Increased Daytime Sleepiness in Childhood Craniopharyngioma Patients, J Clin Endocrinol Metab, 87, 10.1210/jcem.87.8.8751 · DOI · Paper page
- Müller, 2006, Secondary Narcolepsy may be a Causative Factor of Increased Daytime Sleepiness in Obese Childhood Craniopharyngioma Patients, J Pediatr Endocrinol Metab 19(suppl, 10.1055/s-2006-974095 · DOI
- O’Gorman, 2010, Sleep-Disordered Breathing Is Increased in Obese Adolescents With Craniopharyngioma Compared With Obese Controls, J Clin Endocrinol Metab, 95, 10.1210/jc.2009-2003 · DOI · Paper page
- Miller, 2015, Sleep Patterns and Obesity in Childhood, Curr Opin Endocrinol Diabetes Obes, 22, 10.1097/MED.0000000000000125 · DOI · Paper page
- Poretti, 2010, Outcome of Craniopharyngioma in Children: Long-Term Complications and Quality of Life. Dev Med Child Neurol. 2004;46:220–229, Elliott RE, Wisoff JH. Surgical Management of Giant Pediatric craniopharyngiomas, J Neurosurg Pediatr, 46
- Schoenfeld, 2012, The Superiority of Conservative Resection and Adjuvant Radiation for Craniopharyngiomas, J Neurooncol, 108, 10.1007/s11060-012-0806-7 · DOI · Paper page
- Spoudeas, 2006, A Multimodality Approach to the Treatment of Craniopharyngiomas Avoiding Hypothalamic Morbidity: A UK Perspective, J Pediatr Endocrinol Metab
- Zacharia, 2012, Incidence, Treatment and Survival of Patients With Craniopharyngioma in the Surveillance, Epidemiology and End Results Program, Neuro Oncol, 14, 10.1093/neuonc/nos142 · DOI · Paper page
- Sterkenburg, 2015, Survival, Hypothalamic Obesity, and Neuropsychological/Psychosocial Status After Childhood-Onset Craniopharyngioma: Newly Reported Long-Term Outcomes, Neuro Oncol, 17, 10.1093/neuonc/nov044 · DOI · Paper page
- Beltran, 2010, Dosimetric Effect of Target Expansion and Setup Uncertainty During Radiation Therapy in Pediatric Craniopharyngioma, Radiother Oncol, 97, 399, 10.1016/j.radonc.2010.10.017 · doi:10.1016/j.radonc.2010.10.017
- Boehling, 2012, Dosimetric Comparison of Three-Dimensional Conformal Proton Radiotherapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Radiotherapy for Treatment of Pediatric Craniopharyngiomas, Int J Radiat Oncol Biol Phys, 82, 10.1016/j.ijrobp.2010.11.027 · DOI · Paper page
- Beltran, 2012, On the Benefits and Risks of Proton Therapy in Pediatric Craniopharyngioma, Int J Radiat Oncol Biol Phys Feb 1, 82, 10.1016/j.ijrobp.2011.01.005 · DOI
- Winkfield, 2008, Proton Radiotherapy for Childhood Craniopharyngioma: Initial Clinical Outcomes, Int J Radiat Oncol Biol Phys, 72, S496, 10.1016/j.ijrobp.2008.06.1453 · doi:10.1016/j.ijrobp.2008.06.1453
- Chang, 2009, Outcomes of Pediatric Craniopharyngioma Treated With Proton Radiation Therapy, Int J Radiat Oncol Biol Phys, 75, S513, 10.1016/j.ijrobp.2009.07.1170 · doi:10.1016/j.ijrobp.2009.07.1170
- Indelicato, 2012, Proton Therapy for Craniopharyngioma: Early Clinical Outcomes, Int J Radiat Oncol Biol Phys, 84, S634, 10.1016/j.ijrobp.2012.07.1692 · doi:10.1016/j.ijrobp.2012.07.1692
- Merchant, 2016, Necrosis, Vasculopathy, and Neurological Complications After Proton Therapy for Childhood Craniopharyngioma: Results From a Prospective Trial and a Photon Cohort Comparison, Int J Rad Biol Oncol Phys, 96, S12, 10.1016/j.ijrobp.2016.06.294 · doi:10.1016/j.ijrobp.2016.06.294
- Kortmann, 2011, Different Approaches in Radiation Therapy of Craniopharyngioma, Front Endocrinol (Lausanne), 2, 10.3389/fendo.2011.00100 · DOI
- Bishop, 2014, Proton Beam Therapy Versus Conformal Photon Radiation Therapy for Childhood Craniopharyngioma: Multi-Institutional Analysis of Outcomes, Cyst Dynamics, and Toxicity, Int J Radiat Oncol Biol Phys, 90, 10.1016/j.ijrobp.2014.05.051 · DOI · Paper page
- Ramakrishnan, 2016, Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity, J Biol Chem, 291, 10.1074/jbc.M116.745778 · DOI
- Kalina, 2015, Carbohydrate-Lipid Profile and Use of Metformin With Micronized Fenofibrate in Reducing Metabolic Consequences of Craniopharyngioma Treatment in Children: Single Institution Experience, J Pediatr Endocrinol Metab, 28, 45, 10.1515/jpem-2014-0425 · DOI
- Orskov, 1996, Effects of the Somatostatin Analog, Octreotide, on Glucose Metabolism and Insulin Sensitivity in Insulin-Dependent Diabetes Mellitus, Metabolism, 45, 10.1016/S0026-0495(96)90056-6 · DOI
- Lustig, 2003, Octreotide Therapy of Pediatric Hypothalamic Obesity: A Double-Blind, Placebo-Controlled Trial, J Clin Endocrinol Metab, 88, 10.1210/jc.2002-030003 · DOI · Paper page
- Craig, Supplemental NDA 21-008/S-018. Clinical Review
- Silverstone, 1968, The Anorectic Effect of Dexamphetamine Sulphate, Br J Pharmacol Chemother, 33, 10.1111/j.1476-5381.1968.tb00499.x · DOI
- Mead, 2016, Drug Interventions for the Treatment of Obesity in Children and Adolescents, Cochrane Database Syst Rev, 11, CD012436, 10.1002/14651858.CD012436 · DOI · Paper page
- Danielsson, 2007, Impact Sibutramine Therapy in Children With Hypothalamic Obesity or Obesity With Aggravating Syndromes, J Clin Endocrinol Metab, 92, 10.1210/jc.2007-0826 · DOI · Paper page
- Jimenez-Munoz, 2021, Targeting Energy Expenditure-Drugs for Obesity Treatment, Pharmaceut (Basel), 14, 435, 10.3390/ph14050435 · DOI
- Loh, 2017, Human Brown Adipose Tissue as a Target for Obesity Management; Beyond Cold-Induced Thermogenesis, Obes Rev, 18, 10.1111/obr.12584 · DOI
- Dulloo, 1994, Paraxanthine (Metabolite of Caffeine) Mimics Caffeine’s Interaction With Sympathetic Control of Thermogenesis, Am J Physiol, 267, 10.1152/ajpendo.1994.267.5.E801 · DOI
- Clark, 2019, Caffeine Enhances Activity Thermogenesis and Energy Expenditure in Rats, Clin Exp Pharmacol Physiol, 46, 10.1111/1440-1681.13065 · DOI
- Greenway, 2008, Treatment of Hypothalamic Obesity With Caffeine and Ephedrine, Endocr Pract, 14, 697, 10.4158/EP.14.6.697 · DOI · Paper page
- Faraone, 2008, Effect of Stimulants on Height and Weight: A Review of the Literature, J Am Acad Child Adolesc Psychiatry, 47, 994, 10.1097/CHI.0b013e31817e0ea7 · DOI
- Seiden, 1993, Amphetamine: Effects on Catecholamine Systems and Behavior, Annu Rev Pharmacol Toxicol, 33, 10.1146/annurev.pa.33.040193.003231 · DOI · Paper page
- Rowley, 2000, Comparison of the Effects of Sibutramine and Other Weight-Modifying Drugs on Extracellular Dopamine in the Nucleus Accumbens of Freely Moving Rats, Synapse, 38, 10.1002/1098-2396(200011)38:2<167::AID-SYN8>3.0.CO;2-W · doi:10.1002/1098-2396(200011)38:2<167::aid-syn8>3.0.co;2-w
- Roth, 2012, Functional Neuroimaging in Craniopharyngioma: A Useful Tool to Better Understand Hypothalamic Obesity, Obes Facts, 5, 10.1159/000338695 · DOI
- Ismail, 2006, Dexamphetamine Use for Management of Obesity and Hypersomnolence Following Hypothalamic Injury, J Pediatr Endocrinol Metab, 19, 10.1515/JPEM.2006.19.2.129 · DOI
- Denzer, 2019, Treatment of Hypothalamic Obesity With Dextroamphetamine: A Case Series, Obes Facts, 12, 91, 10.1159/000495851 · DOI · Paper page
- Mason, 2002, The Use of Dextroamphetamine to Treat Obesity and Hyperphagia in Children Treated for Craniopharyngioma, Arch Pediatr Adolesc Med, 156, 10.1001/archpedi.156.9.887 · DOI · Paper page
- Yavuz, 2019, Thyroid Hormone Action and Energy Expenditure, J Endocr Soc, 3, 10.1210/js.2018-00423 · DOI
- Cawthon, 2021, The Critical Role of CCK in the Regulation of Food Intake and Diet-Induced Obesity, Peptides, 138, 170492, 10.1016/j.peptides.2020.170492 · DOI
- Zanchi, 2017, The Impact of Gut Hormones on the Neural Circuit of Appetite and Satiety: A Systematic Review, Neurosci Biobehav Rev, 80, 10.1016/j.neubiorev.2017.06.013 · DOI · Paper page
- Barrachina, 1997, Synergistic Interaction Between Leptin and Cholecystokinin to Reduce Short-Term Food Intake in Lean Mice, Proc Natl Acad Sci USA, 94, 10.1073/pnas.94.19.10455 · DOI · Paper page
- McMinn, 2000, Leptin Deficiency Induced by Fasting Impairs the Satiety Response to Cholecystokinin, Endocrinology, 141, 10.1210/endo.141.12.7815 · DOI
- Elfers, 2012, Glucagon-Like Peptide-1 Agonist Exendin-4 Leads to Reduction of Weight and Caloric Intake in a Rat Model of Hypothalamic Obesity, Horm Res Paediatr, 78, 47, 10.1159/000338464 · DOI
- Zoicas, 2013, GLP-1 Analogues as a New Treatment Option for Hypothalamic Obesity in Adults: Report of Nine Cases, Eur J Endocrinol, 168, 699, 10.1530/EJE-12-0997 · DOI
- Lomenick, 2016, A 52-Week Pilot Study of the Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity, Obes (Silver Spring), 24, 10.1002/oby.21493 · DOI
- van Schaik, 2020, Experiences With Glucagon-Like Peptide-1 Receptor Agonist in Children With Acquired Hypothalamic Obesity, Obes Facts, 13, 10.1159/000509302 · DOI
- Roth, 2021, A Phase 3 Randomized Clinical Trial Using a Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist in Adolescents and Young Adults With Hypothalamic Obesity, Diabetes Obes Metab, 23, 10.1111/dom.14224 · DOI · Paper page
- Kanoski, 2017, Hippocampus Contributions to Food Intake Control: Mnemonic, Neuroanatomical, and Endocrine Mechanisms, Biol Psychiat, 81, 10.1016/j.biopsych.2015.09.011 · DOI · Paper page
- Hsu, 2018, Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection, J Clin Endocrinol Metab, 103, 10.1210/jc.2017-02080 · DOI
- Liu, 2021, Oxytocin and Food Intake Control: Neural, Behavioral, and Signaling Mechanisms, Int J Mol Sci, 22, 10859, 10.3390/ijms221910859 · DOI
- Ong, 2015, Medial Nucleus Tractus Solitarius Oxytocin Receptor Signaling and Food Intake Control: The Role of Gastrointestinal Satiation Signal Processing, Am J Physiol Regul Integr Comp Physiol, 308, 10.1152/ajpregu.00534.2014 · DOI
- Caquineau, 2006, Effects of Alpha-Melanocyte-Stimulating Hormone on Magnocellular Oxytocin Neurones and Their Activation at Intromission in Male Rats, J Neuroendocrinol, 18, 10.1111/j.1365-2826.2006.01465.x · DOI
- Maejima, 2018, The Anorexigenic Neural Pathways of Oxytocin and Their Clinical Implication, Neuroendocrinology, 107, 91, 10.1159/000489263 · DOI
- Blevins, 2015, Chronic Oxytocin Administration Inhibits Food Intake, Increases Energy Expenditure, and Produces Weight Loss in Fructose-Fed Obese Rhesus Monkeys, Am J Physiol Regul Integr Comp Physiol, 308, 10.1152/ajpregu.00441.2014 · DOI · Paper page
- Miller, 2017, Oxytocin Treatment in Children With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled, Crossover Study, Am J Med Genet A, 173, 10.1002/ajmg.a.38160 · DOI
- Damen, 2021, Oxytocin in Young Children With Prader-Willi Syndrome: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial Investigating 3 Months of Oxytocin, Clin Endocrinol (Oxf), 94, 10.1111/cen.14387 · DOI
- Solbiati, 1999, Processing of the N Termini of Nascent Polypeptide Chains Requires Deformylation Prior to Methionine Removal, J Mol Biol, 290, 10.1006/jmbi.1999.2913 · DOI
- Selvakumar, 2009, NC2213: A Novel Methionine Aminopeptidase 2 Inhibitor in Human Colon Cancer HT29 Cells, Mol Cancer, 8, 65, 10.1186/1476-4598-8-65 · DOI
- Heinrich, 2019, Identification of Methionine Aminopeptidase-2 (MetAP-2) Inhibitor M8891: A Clinical Compound for the Treatment of Cancer, J Med Chem, 62, 10.1021/acs.jmedchem.9b01070 · DOI
- Joharapurkar, 2014, Inhibition of the Methionine Aminopeptidase 2 Enzyme for the Treatment of Obesity, Diabetes Metab Syndr Obes, 7, 73, 10.2147/DMSO.S56924 · DOI
- White, 2012, The Angiogenic Inhibitor TNP-470 Decreases Caloric Intake and Weight Gain in High-Fat Fed Mice, Obes (Silver Spring), 20, 10.1038/oby.2012.87 · DOI
- Hughes, 2013, Ascending Dose-Controlled Trial of Beloranib, a Novel Obesity Treatment for Safety, Tolerability, and Weight Loss in Obese Women, Obes (Silver Spring), 21, 10.1002/oby.20356 · DOI
- Datta, 2004, Treatment of Cells With the Angiogenic Inhibitor Fumagillin Results in Increased Stability of Eukaryotic Initiation Factor 2-Associated Glycoprotein, P67, and Reduced Phosphorylation of Extracellular Signal-Regulated Kinases, Biochemistry, 43, 10.1021/bi049172p · DOI
- Elfers, 2017, Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity, Endocrinology, 158, 41, 10.1210/en.2016-1665 · DOI
- McCandless, 2017, Effects of MetAP2 Inhibition on Hyperphagia and Body Weight in Prader-Willi Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial, Diabetes Obes Metab, 19, 10.1111/dom.13021 · DOI
- Shoemaker, 2017, A Randomized, Placebo-Controlled Trial of Beloranib for the Treatment of Hypothalamic Injury-Associated Obesity, Diabetes Obes Metab, 19, 10.1111/dom.12928 · DOI
- Lehr, 2008, Contribution of the Active Metabolite M1 to the Pharmacological Activity of Tesofensine In Vivo: A Pharmacokinetic- Pharmacodynamic Modelling Approach, Br J Pharmacol, 153, 10.1038/sj.bjp.0707539 · DOI
- Hansen, 2013, Tesofensine Induces Appetite Suppression and Weight Loss With Reversal of Low Forebrain Dopamine Levels in the Diet-Induced Obese Rat, Pharmacol Biochem Behav, 110, 10.1016/j.pbb.2013.07.018 · DOI
- Hauser, 2007, Randomized Trial of the Triple Monoamine Reuptake Inhibitor NS 2330 (Tesofensine) in Early Parkinson’s Disease, Mov Disord, 22, 10.1002/mds.21258 · DOI
- Astrup, 2008, Weight Loss Produced by Tesofensine in Patients With Parkinson’s or Alzheimer’s Disease, Obes (Silver Spring), 16, 10.1038/oby.2008.56 · DOI
- Astrup, 2008, Effect of Tesofensine on Bodyweight Loss, Body Composition, and Quality of Life in Obese Patients: A Randomised, Double-Blind, Placebo-Controlled Trial, Lancet, 372, 10.1016/S0140-6736(08)61525-1 · DOI · Paper page
- Bentzen, 2013, Antihypertensive Treatment Preserves Appetite Suppression While Preventing Cardiovascular Adverse Effects of Tesofensine in Rats, Obes (Silver Spring), 21, 10.1002/oby.20122 · DOI
- Kim, 2014, Antiobesity Pharmacotherapy: New Drugs and Emerging Targets, Clin Pharmacol Ther, 95, 53, 10.1038/clpt.2013.204 · DOI · Paper page
- Haws, 2021, The Efficacy and Safety of Setmelanotide in Individuals With Bardet-Biedl Syndrome or Alström Syndrome: Phase 3 Trial Design, Contemp Clin Trials Commun, 22, 100780, 10.1016/j.conctc.2021.100780 · DOI
- Markham, 2021, Setmelanotide: First Approval, Drugs, 81, 397, 10.1007/s40265-021-01470-9 · DOI · Paper page
- Haws, 2020, Effect of Setmelanotide, a Melanocortin-4 Receptor Agonist, on Obesity in Bardet-Biedl Syndrome, Diabetes Obes Metab, 22, 10.1111/dom.14133 · DOI
- van Iersel, 2019, Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review, Endocr Rev, 40, 193, 10.1210/er.2018-00017 · DOI · Paper page
- Weismann, 2013, Bariatric Surgery for Morbid Obesity in Craniopharyngioma, Clin Endocrinol (Oxf), 78, 10.1111/j.1365-2265.2012.04409.x · DOI
- Smith, 1983, Truncal Vagotomy in Hypothalamic Obesity, Lancet, 1, 10.1016/S0140-6736(83)92437-6 · DOI
- Pisapia, 2010, Deep Brain Stimulation Compared With Bariatric Surgery for the Treatment of Morbid Obesity: A Decision Analysis Study, Neurosurg Focus, 29, E15, 10.3171/2010.5.FOCUS10109 · DOI
- Oterdoom, 2018, Therapeutic Potential of Deep Brain Stimulation of the Nucleus Accumbens in Morbid Obesity, Neurosurg Focus, 45, E10, 10.3171/2018.4.FOCUS18148 · DOI
- Harat, 2016, Nucleus Accumbens Stimulation in Pathological Obesity, Neurol Neurochir Pol, 50, 10.1016/j.pjnns.2016.01.014 · DOI · Paper page
- Rath, 2013, Childhood Craniopharyngioma: 20-Year Institutional Experience in Western Australia, J Paediatr Child Health, 49, 10.1111/jpc.12190 · DOI
Cited by
Roth, C. L., Scimia, C., Shoemaker, A. H., Gottschalk, M., Miller, J., Yuan, G., Malhotra, S., & Abuzzahab, M. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00087-1 · Cited by 76
Kayadjanian, N., Hsu, E. A., Wood, A. M., & Carson, D. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad488 · Cited by 28
Treatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25
Self-citationvan Santen, H. M., & Müller, H. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf025 · Cited by 21
Metadata
- Authors
- Dimitri, P.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2022-04-06
- Volume
- 13
- ISSN
- 1664-2392
- PMC
- PMC9019363
- Cited by
- 65
- References
- 28
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Acquired Hypothalamic Obesity: Now and the Future. https://app.cochat.ai/papers/10.3389/fendo.2022.846880
- The paper
- Dimitri, P. (2022). Treatment of Acquired Hypothalamic Obesity: Now and the Future. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.846880
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.